[A20-63] Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V

Last updated 02.11.2020

Project no.:
A20-63

Commission:
Commission awarded on 24.07.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Immune system and infections

Indication:

Children from 3 years to < 12 years of age with chronic hepatitis C

Result of dossier assessment:

Genotype 1 and 4: hint of non-quantifiable added benefit; genotype 3, 5 and 6: added benefit not proven

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.